10 Best Immunotherapy Stocks to Buy Now
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 30,739,020 | $2,031,849,222 | +1% | 21.05% |
| 2. | Renaissance Technologies Jim Simons | 4,499,540 | $297,419,594 | -14% | 0.44% |
| 3. | AQR Capital Management Cliff Asness | 2,701,723 | $178,583,897 | +2% | 0.24% |
| 4. | Point72 Asset Management Steve Cohen | 2,369,300 | $156,610,730 | 0.39% | |
| 5. | Armistice Capital Steven Boyd | 2,196,105 | $145,162,541 | +25% | 2.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | Large Shareholder, Director | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | Large Shareholder, Director | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | Large Shareholder, Director | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | Large Shareholder, Director | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | Large Shareholder, Director | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $78.21 | 2,256 | Officer | 58,042 | 2024-11-06 | Filing | |
| $82.00 | 1,424 | Officer | 60,298 | 2024-11-06 | Filing | |
| $63.37 | 382 | Officer | 24,443 | 2024-09-13 | Filing | |
| $62.94 | 572 | Officer | 24,825 | 2024-09-12 | Filing | |
| $62.37 | 7,333 | Officer | 36,390 | 2024-09-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,298,022 | $1,525,672,802 | 0.03% | |
| 2. | 22,519,381 | $1,413,991,932 | 0.03% | |
| 3. | 16,090,421 | $1,010,317,535 | 0.64% | |
| 4. | 10,120,170 | $635,445,474 | 0.03% | |
| 5. | 4,273,448 | $267,633,567 | 0.02% |
News See All
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer medication, Jakafi, expires in 2028.
Incyte Corporation (NASDAQ:INCY) Q3 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Incyte Third Quarter Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Incyte Corporation (NASDAQ:INCY) Q2 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Incyte Second Quarter 2024 Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88.
12 Best S&P 500 Stocks To Buy According to Analysts
In this piece, we will take a look at the 12 best S&P 500 stocks to buy according to analysts.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
5 Biotech Stocks with Huge Potential
In this article, we will take a look at the 5 biotech stocks with huge potential.
Incyte Corporation (NASDAQ:INCY) Q4 2023 Earnings Call Transcript
Incyte Corporation misses on earnings expectations. Reported EPS is $1.06 EPS, expectations were $1.21.
12 Most Promising Gene Editing Stocks According to Hedge Funds
In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds.
Billionaire Hedge Funds
